for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Agenus Inc

AGEN.O

Latest Trade

5.09USD

Change

0.09(+1.80%)

Volume

133,375

Today's Range

5.03

 - 

5.13

52 Week Range

2.50

 - 

6.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.00
Open
5.09
Volume
133,375
3M AVG Volume
77.95
Today's High
5.13
Today's Low
5.03
52 Week High
6.79
52 Week Low
2.50
Shares Out (MIL)
233.11
Market Cap (MIL)
1,165.57
Forward P/E
-18.07
Dividend (Yield %)
--

Next Event

Q3 2021 Agenus Inc Earnings Release

Latest Developments

More

Agenus To Receive $20 Mln Milestone Payment From Bristol Myers Squibb

Agenus Inc - Qtrly Total Revenue $10.7 Mln Versus $26.9 Mln

Agenus Closes $200M Upfront Bms Collaboration And Announces FDA Acceptance Of Ind For Partnered Anti-Tigit Bispecific Antibody, Agen1777

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Agenus Inc

Agenus Inc. (Agenus) is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, neoantigen cancer vaccines (individualized and off-the shelf) platforms and adjuvants. Its anti-PD-1 antibody and first-generation and next generation anti-CTLA-4 antagonists are in clinical development. Its pipeline of pre-clinical assets, which include AGEN1777, an anti-TIGIT bispecific antibody and AGEN1327, an anti-TIGIT monospecific antibody. Its neoantigen vaccine platforms include its heat shock protein (HSP) based Prophage vaccine candidates and its synthetic, neoantigen vaccine candidates, AutoSynVax (ASV) and PhosphoSynVax (PSV). Its neoantigen vaccine platforms include individualized ASV and off-the-shelf PSV, which target antigens expressed across patients and tumors.

Industry

Biotechnology & Drugs

Contact Info

3 Forbes Rd

LEXINGTON, MA

02421-7305

United States

+1.781.6744400

http://agenusbio.com/

Executive Leadership

Garo H. Armen

Chairman of the Board, Chief Executive Officer, Co-Founder

Jennifer S. Buell

President, Chief Operating Officer

Evan D. Kearns

Chief Compliance Officer, Vice President, General Counsel, Corporate Secretary

Christine M. Klaskin

Vice President - Finance

Steven Oday

Chief Medical Officer

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.2K

2020

0.1K

2021(E)

0.3K
EPS (USD)

2018

-1.440

2019

-0.800

2020

-1.050

2021(E)

-0.277
Price To Earnings (TTM)
--
Price To Sales (TTM)
17.00
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-548.63
Return on Equity (TTM)
-120.49

Latest News

Latest News

Bristol-Myers, Eisai in up to $3.1 billion deal to develop cancer drug candidate

Bristol-Myers Squibb Co and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug.

Bristol Myers to pay up to $1.56 billion to develop, sell Agenus's cancer therapy

(This May 18 story corrects payment value in headline and first paragraph to $1.56 billion from $1.38 billion)

BRIEF-Betta Pharmaceuticals Agrees To Obtain Commercialization Rights For Agenus' Drugs

* SAYS IT AGREES TO OBTAIN COMMERCIALIZATION RIGHTS FOR AGENUS' BALSTILIMAB AND ZALIFRELIMAB IN MAINLAND CHINA, HONG KONG, MACAU AND TAIWAN

BRIEF-FDA Clears IND For iNKT Cells To Treat Covid-19 Patients

* AGENUS - AGENTUS ALLOGENEIC INKTS HAVE POTENTIAL TO CLEAR SARS-COV-2 VIRUS, MITIGATE HARMFUL INFLAMMATION

BRIEF-Agenus Reports First Quarter Results and Update

* Q1 EARNINGS PER SHARE ESTIMATE $-0.33 -- REFINITIV IBES DATA

BRIEF-Agenus Receives Fast Track Designation For Balstilimab In Advanced Cervical Cancer

* AGENUS RECEIVES FAST TRACK DESIGNATION FOR BALSTILIMAB IN ADVANCED CERVICAL CANCER

BRIEF-Agenus's Chairman And CEO Said He Would Take His Salary In Stock In Lieu Of Cash For Rest Of 2020

* AGENUS INC - GARO ARMEN, CHAIRMAN AND CEO INDICATED HE WOULD TAKE HIS SALARY IN STOCK IN LIEU OF CASH FOR REST OF 2020

BRIEF-Agenus Reports Q4 Loss Per Share Of $0.22

* AGENUS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Agenus Receives Fast Track Designation For Balstilimab & Zalifrelimab In Advanced Cervical Cancer

* AGENUS RECEIVES FAST TRACK DESIGNATION FOR BALSTILIMAB & ZALIFRELIMAB IN ADVANCED CERVICAL CANCER

BRIEF-Agenus Announces Positive Interim Data From Balstilimab And Zalifrelimab Clinical Trials In Second-Line Cervical Cancer

* AGENUS ANNOUNCES POSITIVE INTERIM DATA FROM BALSTILIMAB AND ZALIFRELIMAB CLINICAL TRIALS IN SECOND-LINE CERVICAL CANCER

Agenus shares soar after cancer therapy deal with Gilead

Shares of Agenus Inc surged as much as 70 percent on Thursday after the company said it would develop and market up to five of its immuno-oncology therapies in partnership with Gilead Sciences Inc.

Gilead, Agenus sign deal to develop immuno-oncology therapies

Gilead Sciences Inc has inked a collaboration agreement with Agenus Inc for the development and marketing of up to five novel immuno-oncology therapies.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up